AI News NQ Analysis

[April Dream] "I'm glad NIPP exists" - Delivering a treatment option for pelvic cancer that everyone can choose

NQ Score 50/100

AI Summary (NQ-processed)

Medcuration's April Dream is to make NIPP, a catheter treatment for pelvic cancer, accessible to all patients by achieving insurance coverage by 2030.

AI analysis data is not yet available.

Frequently Asked Questions

Q: What kind of treatment is NIPP?
A: NIPP is a catheter treatment for pelvic cancer that temporarily isolates pelvic blood flow, locally administers high-concentration anticancer drugs, and then collects them, aiming to treat cancer while minimizing systemic side effects.
Q: Why is NIPP currently an expensive self-pay treatment?
A: Due to past stricter regulations on off-label use and halted clinical trials, NIPP is not currently covered by insurance, costing 4 to 5 million yen per session.
Q: What is Medcuration doing to promote NIPP?
A: Medcuration aims for insurance coverage by 2030, preparing for investigator-initiated clinical trials, developing dedicated medical devices, collaborating with PMDA, and establishing multi-institutional research systems.